Press Releases

Uncategorized

EASTGATE BIOTECH CREATES AN ONLINE DIRECTORY AS A MARKETING TOOL FOR ITS NUTRACEUTICAL PRODUCT

SALT LAKE CITY, UT and TORONTO, ON–(Marketwired – September 24, 2015) – EastGate Biotech Corp. (OTC PINK: ETBI), an emerging pharmaceutical company aimed at utilizing drug delivery innovations in the development of improved novel formulations and alternative dosage forms of existing biologically active molecules created an online directory for stores carrying E-drops, marketed as UTI drops by our Canadian distributor, Preferred Nutrition Inc. (www.pno.ca).

The online directory is http://utidrops.com whereat visitors can search for stores carrying UTI drops.  At the moment 265 locations are currently listed.   The directory will allow store owners to enter information such as the description of their business, operating hours, links to website, social media.   An article on UTI drops written by Dr. Gifford Jones also appears on the site.

Preferred Nutrition Inc. is a Canadian premier distribution company founded in 2002.  It primarily distributes to approximately1,200 health food stores across Canada.  It represents 5 top product lines for a total of 78 products in the vitamin and supplement category.

Preferred Nutrition has started marketing E-drops, under their own UTI brand, which is a natural and herbal alternative that assists to rid the body of UTI infections painlessly and effectively without side effects of synthetic drugs.

“This marketing tool will assist store owners and customers alike,” says Anna Gluskin, EastGate Biotech’s CEO.    “It will assist our distributor to track the distribution network with qualified user accounts.  We hope to adopt this for other markets as well as our nutraceutical/consumer product pipeline,” continues Gluskin.

 

Cautionary statement on forward-looking information

All statements, other than statements of historical fact, contained or incorporated by reference in this news release constitute “forward-looking information” or “forward-looking statements” within the meaning of certain securities laws, including the provisions for “safe harbour” under the United States Private Securities Litigation Reform Act of 1995 and are based on expectations, estimates and projections as of the date of this news release.

The words “anticipates,” “plans,” “expects,” “indicate,” “intend,” “scheduled,” “estimates,” “forecasts,” “focus,” “guidance,” “initiative,” “model,” “methodology,” “outlook,” “potential,” “projected,” “pursue,” “strategy,” “study,” “targets,” or “believes,” or variations of or similar such words and phrases or statements that certain actions, events or results “may,” “could,” “would,” or “should,” “might,” or “way forward,” “will be taken,” “will occur” or “will be achieved” and similar expressions identify forward-looking statements. Forward-looking statements are necessarily based upon a number of estimates and assumptions that are inherently subject to significant business, economic and competitive risks, uncertainties and contingencies. The risks, estimates, models and assumptions contained or incorporated by reference in this release, include those identified from time to time in the reports filed by EastGate with the SEC, which should be considered together with any forward-looking statement. EastGate undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

CONTACT:  Rose Perri 1-647-692-0652
Email:  
information@eastgatepharmaceuticals.com
Website: 
www.EastGateBiotech.com

Leave a Reply

Your email address will not be published. Required fields are marked *

Sidebar